Literature DB >> 15356916

CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection.

W M J M Bogers1, L A Bergmeier, H Oostermeijer, P ten Haaft, Y Wang, C G Kelly, M Singh, J L Heeney, T Lehner.   

Abstract

Cell-surface CCR5 is a major coreceptor with CD4 glycoprotein, mediating cellular entry of CCR5 strains of HIV-1 or SIV. We targeted the SIV CCR5 coreceptor in a combined CCR5-SIV antigen immunization strategy. Rhesus macaques were immunized i.m. with the 70 kDa heat shock protein (HSP70) covalently linked to the CCR5 peptides, SIV gpl20 and p27. Intravenous challenge with SIV mac 8980 prevented SIV infection or decreased the viral load with the CCR5-SIV combined vaccine. CC chemokines and antibodies which block and downmodulateCCR5 were induced, as well as immune responses to the subunit SIV antigens. This novel vaccination strategy complements cognate immunity to SIV with innate immunity to the CCR5 coreceptor of SIV.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15356916     DOI： 10.1016/j.vaccine.2004.02.050

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

1.  Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426.

Authors:  Kaboutar Babaahmady; Wulf Oehlmann; Mahavir Singh; Thomas Lehner
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72.

Authors:  Alexzander Asea
Journal:  Curr Immunol Rev       Date:  2006-08

3.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

4.  Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.

Authors:  Claudia Pastori; Lorenzo Diomede; Assunta Venuti; Gregory Fisher; Jonathan Jarvik; Morgane Bomsel; Francesca Sanvito; Lucia Lopalco
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 5.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

6.  Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy.

Authors:  Gene M Shearer; Adriano Boasso
Journal:  F1000 Med Rep       Date:  2011-06-01

7.  Intralymphatic immunotherapy.

Authors:  Gabriela Senti; Thomas M Kündig
Journal:  World Allergy Organ J       Date:  2015-03-07       Impact factor: 4.084

8.  A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody.

Authors:  Benny Chain; Jack Arnold; Samia Akthar; Michael Brandt; David Davis; Mahdad Noursadeghi; Thabo Lapp; Changhua Ji; Surya Sankuratri; Yanjing Zhang; Lata Govada; Emmanuel Saridakis; Naomi Chayen
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

9.  HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor.

Authors:  Benjamin M Chain; Mahdad Noursadeghi; Michelle Gardener; Jhen Tsang; Edward Wright
Journal:  Vaccine       Date:  2008-08-31       Impact factor: 3.641

10.  A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection.

Authors:  Yufei Wang; Trevor Whittall; Stuart Neil; Gary Britton; Mukesh Mistry; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Xuesong Yu; Alicia Sato; Robert J O'Connell; Nelson L Michael; Merlin L Robb; Jerome H Kim; Thomas Lehner
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.